Adiponectin secretion enhancer
US10695360B2 · kind B2 · utility
2Cited by
1References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 15, 2018 |
| Grant date | Jun 30, 2020 |
| Priority date | — |
| Expiry date | Feb 15, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K8/675
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides for the administration of β-NMN, which increases the secretion of adiponectin. The present disclosure also provides an adiponectin secretion enhancer comprising β-nicotinamide mononucleotide, a pharmaceutically acceptable salt thereof or a solvate thereof, and a dietary supplement containing the aforementioned secretion enhancer, which can be ingested in order to increase the secretion of adiponectin. Also disclosed are methods of treating insulin resistance-related diseases such as of metabolic syndrome, diabetes, hyperlipidemia, fatty liver disease, hypertension, obesity, and arteriosclerosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.